European Journal of Biomedical and Pharmaceutical Sciences

THROMBOTIC COMPLICATIONS IN PATIENTS WITH COVID-19

Dr. Danial Rizvi, Dr. Deepali Rahul Raut, Suraj Sapkota, Claudville Dean Derby, Dr. Michaela Nicole C. San Juan, Jeremy Steen, Yeduru Divya Reddy, Nithin Janagam, Kevin Murray*

ABSTRACT

Introduction: COVID 19 has been found to be related to thrombotic events in several studies, although the relationship between the coagulation marker ratio and disease severity remains unclear. Objective: To identify thrombotic complications and coagulation laboratory alterations in hospitalized patients with SARS-CoV-2 infection, according to disease severity. Methodology: PubMed was searched for clinical articles evaluating coagulation and thrombotic laboratory characteristics of patients with COVID-19 according to severity, using MeSH terms and Boolean operators. One investigator filtered the articles following the PRISMA guideline. Results: D-dimer is significantly higher in patients with severe vs. non-severe COVID-19, which may be associated with disease prognosis. There is little evidence about thrombotic complications in COVID-19, but apparently the risk of PTE and DVT is increased in patients with severe disease. Recommendations: Serial measurement of coagulation laboratory parameters from admission, mainly D-dimer and clotting times, should be included in the management protocol for all patients with COVID-19. Strict monitoring of venous thrombotic events in patients with COVID-19, especially in patients with ICU stay, mechanical ventilation or ARDS.

Keywords: COVID-19, coronavirus, thrombosis, hypercoagulability.